ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,037.88
      0.72%
      US Tech 100
      20,795.20
      -0.88%
      Dow Jones
      44,556.04
      0.30%
      Brent Oil
      75.435
      -0.66%
      Bitcoin
      97,892.10
      0.03%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Stoke Therapeutics Inc (STOK) Quote

      Stoke Therapeutics Inc

      Stoke Therapeutics Inc (STOK)

      NASDAQ
      12.60
      1.08
      (9.38%)
      Closed February 04 4:00PM
      Delayed by 15 minutes
      12.00
      -0.60
      ( -4.76% )
      Pre Market: 5:40AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      12.00
      Bid
      7.00
      Ask
      14.75
      Volume
      181
      0.00 Day's Range 0.00
      4.09 52 Week Range 17.58
      Market Cap
      635.604M
      Previous Close
      12.60
      Open
      -
      Last Trade
      1
      @
      12.11
      Last Trade Time
      05:40:30
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      744,561
      Shares Outstanding
      52,966,977
      Dividend Yield
      -
      PE Ratio
      -6.37
      Earnings Per Share (EPS)
      -1.98
      Revenue
      8.78M
      Net Profit
      -104.7M

      About Stoke Therapeutics Inc

      Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.stoketherapeutics.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      Stoke Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STOK. The last closing price for Stoke Therapeutics was $12.60. Over the last year, Stoke Therapeutics shares have traded in a share price range of $ 4.09 to $ 17.58.

      Stoke Therapeutics currently has 52,966,977 shares outstanding. The market capitalization of Stoke Therapeutics is $667.38 million. Stoke Therapeutics has a price to earnings ratio (PE ratio) of -6.37.

      Ask ADVFN Intelligence (AI)

      Stoke Therapeutics (STOK) Options Flow Summary

      STOK Options Flow

      Overall Flow

      Bullish

      Net Premium

      498k

      Calls / Puts

      100.00%

      Buys / Sells

      250.00%

      OTM / ITM

      0.00%

      Sweeps Ratio

      0.00%

      STOK Latest News

      More News

      Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management...

      January 08 2025
      Business Wire

      Form 8-K - Current report

      January 07 2025
      Edgar (US Regulatory)

      Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

      – Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for EMPEROR – – One-year study of...

      January 07 2025
      Business Wire

      Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

      Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that its...

      January 06 2025
      Business Wire

      Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

      December 27 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 27 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      December 23 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 11 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 11 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 10 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      12.222.44897959189.812.859.760188009711.62212606CS
      42.5827.38853503189.4212.858.4285557510.04411403CS
      12-1.765-12.822375590313.76514.728.4274456111.16250776CS
      26-0.92-7.1207430340612.9216.158.4261302912.30221595CS
      527.43162.5820568934.5717.584.0980570412.39732454CS
      156-5.15-30.02915451917.1526.63.3546439011.75073128CS
      260-17.05-58.691910499129.0571.583.3534390715.76372488CS

      STOK - Frequently Asked Questions (FAQ)

      What is the current Stoke Therapeutics share price?
      The current share price of Stoke Therapeutics is $ 12.00
      How many Stoke Therapeutics shares are in issue?
      Stoke Therapeutics has 52,966,977 shares in issue
      What is the market cap of Stoke Therapeutics?
      The market capitalisation of Stoke Therapeutics is USD 667.38M
      What is the 1 year trading range for Stoke Therapeutics share price?
      Stoke Therapeutics has traded in the range of $ 4.09 to $ 17.58 during the past year
      What is the PE ratio of Stoke Therapeutics?
      The price to earnings ratio of Stoke Therapeutics is -6.37
      What is the cash to sales ratio of Stoke Therapeutics?
      The cash to sales ratio of Stoke Therapeutics is 76
      What is the reporting currency for Stoke Therapeutics?
      Stoke Therapeutics reports financial results in USD
      What is the latest annual turnover for Stoke Therapeutics?
      The latest annual turnover of Stoke Therapeutics is USD 8.78M
      What is the latest annual profit for Stoke Therapeutics?
      The latest annual profit of Stoke Therapeutics is USD -104.7M
      What is the registered address of Stoke Therapeutics?
      The registered address for Stoke Therapeutics is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
      What is the Stoke Therapeutics website address?
      The website address for Stoke Therapeutics is www.stoketherapeutics.com
      Which industry sector does Stoke Therapeutics operate in?
      Stoke Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      OPOFOld Point Financial Corporation
      $ 39.51
      (58.99%)
      		4
      TWINTwin Disc Inc
      $ 17.88
      (58.93%)
      		168
      IBACIB Acquisition Corporation
      $ 16.24
      (58.90%)
      		54
      ADSEADD TEC Energy PLC
      $ 23.39
      (56.66%)
      		12
      AFRIForafric Global PLC
      $ 14.99
      (56.15%)
      		19
      SBFGSB Finanical Group Inc
      $ 12.22
      (-46.85%)
      		10
      THRYThryv Holdings Inc
      $ 10.01
      (-46.01%)
      		4
      AURAAura Biosciences Inc
      $ 5.01
      (-37.38%)
      		1
      LSBKLake Shore Bancorp Inc
      $ 11.01
      (-30.23%)
      		1
      INBXInhibrx Biosciences Inc
      $ 9.01
      (-30.21%)
      		30
      SXTP60 Degrees Pharmaceuticals Inc
      $ 0.8937
      (49.70%)
      		18.58M
      CYNCYNGN Inc
      $ 0.0808
      (13.80%)
      		16.67M
      UPCUniverse Pharmaceuticals Inc
      $ 0.3122
      (15.67%)
      		8.97M
      ASSTAsset Entities Inc
      $ 0.75
      (36.54%)
      		7.11M
      SFHGSamfine Creation Holdings Group Ltd
      $ 1.48
      (48.00%)
      		6.69M

      STOK Discussion

      View Posts
      PonkenPlonken PonkenPlonken 2 months ago
      I am so STOKED about this company. They were doing this before they all figured out you need RNA science for gene therapy.
      See SRPT ARWR deal! another AAV based gene tx seeking RNAI
      👍️0
      Monksdream Monksdream 5 months ago
      FOLD under $15
      👍️0
      Zardiw Zardiw 10 months ago
      $STOK Chart from #DDAmanda - #1 Stock Screener :

      Scans are preset. Push a Button. Find Winners Early:



      Z
      👍️0
      TimeFades TimeFades 10 months ago
      Choppy day shoulda just stuck with my morning short
      👍️0
      TimeFades TimeFades 10 months ago
      Got bullish again and covered
      👍️0
      TimeFades TimeFades 10 months ago
      Short from 12s
      👍️0
      Invest-in-America Invest-in-America 10 months ago
      STOK: "Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a genetic form of epilepsy. The biotech company said data from two Phase 1/2a studies and two open label extension, or OLE, studies showed “clinically meaningful effects” that included “substantial and durable reductions in convulsive seizure frequency."
      https://seekingalpha.com/news/4083468-stoke-stock-soars-post-market-on-epilepsy-drug-data

      Dravet Syndrome is an extremely RARE disease in the USA. And the above news does NOT specify nor suggest that STOK's (potential) treatment for Dravet Syndrome will or might have any applications for treatment of EPILEPSY at all. (Be very CAREFUL about news like the above.)
      👍️0

      Your Recent History

      NASDAQ
      STOK
      Stoke Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads